PD-1 ligands, PD-L1/L2 are expressed in several tumor types, and the interaction with its receptor triggers effector T cell function inhibition and T cell exhaustion, developing a suppressive microenvironment which prevents antitumor activity. The gene discussed is PDCD1; the disease is neoplasm.